Partner 6 – CURE
CureVac is developing mRNA-molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases based on its proprietary technology. The company is a mid-sized biotech company with comprehensive funding largely by the investor D. Hopp (co-founder SAP). The preclinical development of CureVac mRNA vaccines led to three clinical phase I/IIa trials in advanced non-small cell lung cancer (NSCLC) and prostate carcinoma with vaccines targeting tumour associated self-antigens. CureVac has built up a unique standardized GMP production facility, allowing for production of long-chain RNA molecules. Therefore, supply of RNAdjuvant® in GMP quality as drug product for patient treatment is expected to be possible within this facility.
Dr. Regina Heidenreich